FDA go ahead for Eli Lilly’s therapy for hard-to-treat ovarian cancer
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
Subscribe To Our Newsletter & Stay Updated